UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML

American journal of hematology, 2011-07, Vol.86 (7), p.533-539

2011

Link zum Volltext

Verfügbarkeit prüfen

N‐terminal pro‐brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia

American journal of hematology, 2023-02, Vol.98 (2), p.290-299

2023

Link zum Volltext

Verfügbarkeit prüfen

Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis

Clinical chemistry (Baltimore, Md.), 2018-03, Vol.64 (3), p.547-555

2018

Link zum Volltext

Verfügbarkeit prüfen

CD34+/CD38− stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin

Haematologica (Roma), 2012-02, Vol.97 (2), p.219-226

2012

Link zum Volltext

Verfügbarkeit prüfen

Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily

Haematologica (Roma), 2011-01, Vol.96 (1), p.163-166

2011

Link zum Volltext

Verfügbarkeit prüfen

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

Blood, 2021-03, Vol.137 (10), p.1365-1376

2021

Link zum Volltext

Verfügbarkeit prüfen

Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study

Leukemia, 2022-07, Vol.36 (7), p.1834-1842

2022

Link zum Volltext

Verfügbarkeit prüfen

Current diagnostic requirements in chronic myeloid leukemia

Wiener medizinische Wochenschrift, 2013-11, Vol.163 (21-22), p.477

2013

Link zum Volltext

Verfügbarkeit prüfen

Aktuelle Anforderungen an die Diagnostik bei chronisch myeloischer Leukämie

Wiener medizinische Wochenschrift, 2013-11, Vol.163 (21-22), p.477-494

2013

Link zum Volltext

Verfügbarkeit prüfen

NT-Probnp As Personalized Medicine Tool and New Biomarker Predicting Response to Chemotherapy and Survival in AML

Blood, 2021-11, Vol.138 (Supplement 1), p.3435-3435

2021

Link zum Volltext

Verfügbarkeit prüfen

The biological and clinical significance of MLL abnormalities in haematological malignancies

European journal of clinical investigation, 2004-08, Vol.34 (s2), p.12-24

2004

Link zum Volltext

Verfügbarkeit prüfen

Digital Droplet PCR: Next Generation KIT D816V Testing As Advanced Tool for Diagnosis and Prognostication in Mastocytosis

Blood, 2017-12, Vol.130, p.2927-2927

2017

Link zum Volltext

Verfügbarkeit prüfen

Co-occurrence of immature T-lymphoblastic lymphoma and acute myeloid leukemia—microenvironment-dependent lineage differentiation derived from a common progenitor?

Journal of hematopathology, 2021-12, Vol.14 (4), p.325-332

2021

Link zum Volltext

Verfügbarkeit prüfen

Cold antibody autoimmune hemolytic anemia and lymphoproliferative disorders: a retrospective study of 20 patients including clinical, hematological, and molecular findings

Wiener Klinische Wochenschrift, 2014-06, Vol.126 (11-12), p.376-382

2014

Link zum Volltext

Verfügbarkeit prüfen

Endogenous erythroid colony formation in chronic myeloid leukemia: a recurrent finding associated with persistent minimal residual disease under imatinib

Stem cells and development, 2013-12, Vol.22 (23), p.3043

2013

Link zum Volltext

Verfügbarkeit prüfen

The Leukemic Stem Cell (LSC) in Ph+ CML Is a CD34+/CD38−/Lin− Cell That Co-Expresses Dipeptidylpeptidase IV (CD26) and Disrupts LSC-Niche Interactions by Degrading the CXCR4 Ligand SDF-1α

Blood, 2011-11, Vol.118 (21), p.961-961

2011

Link zum Volltext

Verfügbarkeit prüfen

BCR/ABL+ CML Stem Cells (CD34+/CD38-) Express High Levels of CD33 and Are Responsive to a CD33-Targeting Drug: a New Potential Concept for Eradication of CML Stem Cells

Blood, 2010-11, Vol.116 (21), p.3382-3382

2010

Link zum Volltext

Verfügbarkeit prüfen

Stable non-transforming minimal residual disease in Philadelphia chromosome positive acute lymphoblastic leukemia after autologous transplantation: origin from neoplastic yet 'pre-leukemic' stem cells?

Leukemia & lymphoma, 2011-05, Vol.52 (5), p.842-848

2011

Link zum Volltext

Verfügbarkeit prüfen

Molecular Disease Eradication is a Prerequisite for Long-term Remission in Patients with t(8;21) Positive Acute Myeloid Leukemia: a Single Center Study

Leukemia & lymphoma, 2004-05, Vol.45 (5), p.971-977

2004

Link zum Volltext

Verfügbarkeit prüfen

Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis

American journal of cancer research, 2011-01, Vol.1 (4), p.531-541

2011

Link zum Volltext

Verfügbarkeit prüfen

Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe

Blood, 2010-11, Vol.116 (21), p.894-894

2010

Link zum Volltext

Verfügbarkeit prüfen

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

Blood, 2010-11, Vol.116 (21), p.893-893

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(24)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Humans
(15)
Hematology
(11)
Female
(9)
Male
(9)
Middle Aged
(9)
Adult
(7)
Aged
(7)
Treatment Outcome
(7)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Drug Therapy
(5)
Oncology
(5)
Biological And Medical Sciences
(4)
Hematologic And Hematopoietic Diseases
(4)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(4)
Medical Sciences
(4)
Acute Disease
(3)
Aged, 80 And Over
(3)
Chronic Myeloid Leukemia
(3)
Dasatinib
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML

N‐terminal pro‐brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia

Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis

KIT-D816V–independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib

CD34+/CD38− stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin

Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study

Current diagnostic requirements in chronic myeloid leukemia

Aktuelle Anforderungen an die Diagnostik bei chronisch myeloischer Leukämie

NT-Probnp As Personalized Medicine Tool and New Biomarker Predicting Response to Chemotherapy and Survival in AML

The biological and clinical significance of MLL abnormalities in haematological malignancies

Digital Droplet PCR: Next Generation KIT D816V Testing As Advanced Tool for Diagnosis and Prognostication in Mastocytosis

Co-occurrence of immature T-lymphoblastic lymphoma and acute myeloid leukemia—microenvironment-dependent lineage differentiation derived from a common progenitor?

Cold antibody autoimmune hemolytic anemia and lymphoproliferative disorders: a retrospective study of 20 patients including clinical, hematological, and molecular findings

Umbilical Cord Blood Transplantation Is a Feasible Rescue Therapeutic Option for Patients Suffering from Graft Failure after Previous Hematopoietic Stem Cell Transplantation

Endogenous erythroid colony formation in chronic myeloid leukemia: a recurrent finding associated with persistent minimal residual disease under imatinib

The Leukemic Stem Cell (LSC) in Ph+ CML Is a CD34+/CD38−/Lin− Cell That Co-Expresses Dipeptidylpeptidase IV (CD26) and Disrupts LSC-Niche Interactions by Degrading the CXCR4 Ligand SDF-1α

BCR/ABL+ CML Stem Cells (CD34+/CD38-) Express High Levels of CD33 and Are Responsive to a CD33-Targeting Drug: a New Potential Concept for Eradication of CML Stem Cells

Stable non-transforming minimal residual disease in Philadelphia chromosome positive acute lymphoblastic leukemia after autologous transplantation: origin from neoplastic yet 'pre-leukemic' stem cells?

Molecular Disease Eradication is a Prerequisite for Long-term Remission in Patients with t(8;21) Positive Acute Myeloid Leukemia: a Single Center Study

Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis

Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

Suchergebnisse filtern